As of the close of September 30, 2024, the total market value of Mindray Medical is 355.2 billion yuan. Data shows that Mindray Medical's performance (revenue, net profit) has repeatedly reached new highs in recent years, maintaining a growth rate of over 10%. In the first half of 2024, its revenue exceeded 20 billion yuan, net profit exceeded 7 billion yuan, and it also provided nearly 5 billion yuan in cash dividends.

 

 

 

It is reported that Mindray Medical is one of the earliest medical device companies in China to go global. As early as 2000, the company began its global layout. After more than 20 years of continuous development, the company has established 63 overseas subsidiaries in about 40 countries in North America, Europe, Asia, Africa, Latin America and other regions, building a global R&D, marketing and service network. Mindray Medical has also demonstrated extraordinary strategic vision in the integration of global resources. Through mergers and partnerships, the company continuously strengthens its position in the global industrial chain.

 

 

 

Mindray Medical has stated at an investor event that based on continuous localization construction and breakthroughs in high-end customers, it is expected that the overseas market will continue to maintain a rapid growth trend in the second half of the year and for a considerable period of time in the future, especially in developing countries and European markets. The company still has strong confidence in being able to follow the established plan.

 

 

 

Hengrui Pharmaceutical has returned to the 300 billion yuan market value mark, with a total market value of 333.6 billion yuan as of the close on September 30, 2024. It is reported that since its listing in 2000, Hengrui Pharmaceutical's stock price and performance have been soaring. However, since 2021, due to relevant factors, Hengrui Pharmaceutical, which is undergoing transformation and upgrading, has been under pressure in terms of performance and its stock price has rebounded. However, in 2023, Hengrui Pharmaceutical achieved positive performance growth and emerged from the previous downward trend, showing initial results in expanding its innovative drug market. In the first half of 2024, Hengrui Pharmaceutical delivered a better half year report since its listing, with both revenue and net profit reaching new highs for the same period.

 

 

 

In the first half of 2024, Hengrui Pharmaceutical's innovative drug revenue (including tax, excluding external licensing revenue) was 6.612 billion yuan, and the external licensing revenue was 160 million euros. According to estimates, the combined revenue from the two innovations accounts for over half of the total revenue, becoming the main engine driving its performance growth. This means that Hengrui Pharmaceutical has reached an important milestone in its innovative transformation.

 

 

 

Recently, Hengrui Pharmaceutical's new products have also repeatedly reported good news. On September 30th, the company announced that its subsidiary Guangdong Hengrui Pharmaceutical's SHR-1905 injection has been approved for clinical trials and will conduct clinical trials on asthma in adolescents aged 12-17. Prior to this, its subsidiaries Tianjin Hengrui Pharmaceutical's fluoride [18F] metoprolol injection, Shanghai Hengrui Pharmaceutical, and Shandong Shengdi Pharmaceutical's HRS-2129 tablets were approved for clinical use; The production of Ruilafpu - α injection and Ruikangtrastuzumab for injection from Suzhou Shengdia Biopharmaceutical is under review; The SHR-1918 injection from Beijing Shengdi Pharmaceutical and Suzhou Shengdi Biopharmaceutical has been included in the proposed breakthrough treatment varieties.

 

 

 

As of the close of September 30, 2024, BeiGene's total market value is 248.9 billion yuan. It is reported that BeiGene has gradually entered a harvest period for innovative drugs by continuously increasing research and development investment. According to the financial report, in the first half of 2024, BeiGene achieved a total operating revenue of 11.996 billion yuan, a year-on-year increase of 65.4%; The net profit attributable to the owners of the parent company was a loss of 2.877 billion yuan, compared to a loss of approximately 5.219 billion yuan in the same period last year.

 

 

 

In the first half of the year, BeiGene's product revenue was 11.908 billion yuan, an increase of 77.8% compared to the same period last year's 6.696 billion yuan. The growth in product revenue is mainly due to the sales growth of independently developed products such as Zebutinib Capsules (trade name: Baiyueze) and Trebizumab Injection (trade name: Baize An), as well as authorized products from Anjin. The global sales of Zebutinib totaled 8.018 billion yuan, a year-on-year increase of 122.0%.

 

 

 

It is reported that Baekje China also said in its semi annual report that the company is currently promoting more than 15 solid tumor innovation pipelines, including ADC, multi specific antibody and targeted therapy for lung cancer, breast cancer and gastrointestinal cancer.

 

 

 

Except for the three pharmaceutical companies mentioned above, as of the close of September 30, 2024, the total market value of Pianzaihuang is 156 billion yuan, WuXi AppTec is 152.5 billion yuan, Aier Ophthalmology is 148.4 billion yuan, Yunnan Baiyao is 108.8 billion yuan, Lianying Medical is 105.5 billion yuan, and Wantai Biotechnology is 103.6 billion yuan.